Semanteon Capital Management LP Sells 91,698 Shares of Alphatec Holdings, Inc. $ATEC

Semanteon Capital Management LP decreased its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 89.6% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,624 shares of the medical technology company’s stock after selling 91,698 shares during the quarter. Semanteon Capital Management LP’s holdings in Alphatec were worth $118,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Nuveen LLC purchased a new position in shares of Alphatec in the 1st quarter worth approximately $135,874,000. Vanguard Group Inc. grew its stake in Alphatec by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 6,014,772 shares of the medical technology company’s stock valued at $60,990,000 after purchasing an additional 45,792 shares during the period. American Century Companies Inc. increased its position in shares of Alphatec by 16.9% during the 1st quarter. American Century Companies Inc. now owns 5,830,031 shares of the medical technology company’s stock valued at $59,117,000 after purchasing an additional 840,974 shares during the last quarter. Royal Bank of Canada raised its stake in shares of Alphatec by 10.8% during the 1st quarter. Royal Bank of Canada now owns 3,527,939 shares of the medical technology company’s stock worth $35,773,000 after purchasing an additional 342,656 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Alphatec by 7.4% in the 2nd quarter. Geode Capital Management LLC now owns 2,697,541 shares of the medical technology company’s stock worth $29,946,000 after buying an additional 185,297 shares during the last quarter. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ATEC has been the topic of a number of research analyst reports. Needham & Company LLC boosted their target price on shares of Alphatec from $16.00 to $22.00 and gave the company a “buy” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. began coverage on Alphatec in a research note on Friday, October 24th. They issued an “overweight” rating and a $19.00 target price on the stock. Canaccord Genuity Group upped their price target on Alphatec from $20.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, October 31st. Barclays lifted their price objective on Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a report on Monday, November 3rd. Finally, HC Wainwright lifted their target price on shares of Alphatec from $20.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Nine analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Alphatec presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Alphatec Trading Down 2.3%

Shares of Alphatec stock opened at $19.74 on Monday. The company’s 50-day moving average price is $16.06 and its 200-day moving average price is $13.92. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22. Alphatec Holdings, Inc. has a 12-month low of $8.18 and a 12-month high of $21.16. The company has a market cap of $2.93 billion, a price-to-earnings ratio of -17.47 and a beta of 1.17.

Alphatec (NASDAQ:ATEC) last posted its earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period last year, the company posted ($0.28) EPS. The business’s revenue was up 30.4% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. On average, equities analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder Jennifer N. Pritzker sold 250,000 shares of Alphatec stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total transaction of $5,200,000.00. Following the completion of the sale, the insider owned 11,145,045 shares in the company, valued at approximately $231,816,936. This trade represents a 2.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director David R. Pelizzon sold 250,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $20.80, for a total transaction of $5,200,000.00. Following the completion of the transaction, the director owned 11,145,045 shares in the company, valued at approximately $231,816,936. This trade represents a 2.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 1,828,823 shares of company stock worth $33,815,195. 20.90% of the stock is owned by corporate insiders.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.